Condition: SST2-positive Neuroendocrine Neoplasms · Neuroendocrine Tumors · Neuroendocrine Neoplasm · Sponsor: Crinetics Pharmaceuticals Inc.
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
This description comes directly from the study's public registry record.
Contact if you are a potential participant or caregiver · 833-827-9741 · studyinfo@crinetics.com
Contact if you are an HCP/clinical site staff/other · 833-827-9741 · clinicalsites@crinetics.com
Always discuss trial participation with your own doctor first.
| Crinetics Study Site | Phoenix, Arizona, United States | Recruiting |
| Crinetics Study Site | Duarte, California, United States | Recruiting |
| Crinetics Study Site | Newport Beach, California, United States | Recruiting |
| Crinetics Study Site | Orange, California, United States | Recruiting |
| Crinetics Study Site | San Francisco, California, United States | Recruiting |
| Crinetics Study Site | Denver, Colorado, United States | Recruiting |
| Crinetics Study Site | New Haven, Connecticut, United States | Recruiting |
| Crinetics Study Site | Atlanta, Georgia, United States | Recruiting |
| Crinetics Study Site | Lexington, Kentucky, United States | Recruiting |
| Crinetics Study Site | Metairie, Louisiana, United States | Recruiting |
| Crinetics Study Site | Detroit, Michigan, United States | Recruiting |
| Crinetics Study Site | Grand Rapids, Michigan, United States | Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07129252